innohep 10.000 anti xa iu/0.5ml solution for injection
leo pharma a/s (0000003363) 55 industriparken, ballerup, 2750 - tinzaparin sodium - solution for injection - 10.000 anti xa iu/0.5ml - tinzaparin sodium (8000001401) 20000.000000000000iu axa
advantan 0.1% (w/v) cutaneous solution
leo pharma a/s (0000003363) 55 industriparken, ballerup, 2750 - methylprednisolone aceponate - cutaneous solution - 0.1% (w/v) - methylprednisolone aceponate (8000002206) 1mg
advantan 0.1% (w/w) cream
leo pharma a/s (0000003363) 55 industriparken, ballerup, 2750 - methylprednisolone aceponate - cream - 0.1% (w/w) - methylprednisolone aceponate (8000002206) 1mg
advantan 0.1% (w/w) emulsion, cutaneous
leo pharma a/s (0000003363) 55 industriparken, ballerup, 2750 - methylprednisolone aceponate - emulsion, cutaneous - 0.1% (w/w) - methylprednisolone aceponate (8000002206) 1mg
innohep 14.000 anti-xa iu/0.7ml solution for injection in prefilled syringe
leo pharma a/s (0000003363) 55 industriparken, ballerup, 2750 - tinzaparin sodium - solution for injection in prefilled syringe - 14.000 anti-xa iu/0.7ml - tinzaparin sodium (8000001401) 14iu
innohep 18.000 anti-xa iu/0.9ml solution for injection in prefilled syringe
leo pharma a/s (0000003363) 55 industriparken, ballerup, 2750 - tinzaparin sodium - solution for injection in prefilled syringe - 18.000 anti-xa iu/0.9ml - tinzaparin sodium (8000001401) 18iu
innohep 4.500 anti-xa iu/0.45ml solution for injection in prefilled syringe
leo pharma a/s (0000003363) 55 industriparken, ballerup, 2750 - tinzaparin sodium - solution for injection in prefilled syringe - 4.500 anti-xa iu/0.45ml - tinzaparin sodium (8000001401) 4,5iu
innohep 10.000 anti-xa iu/0.5ml solution for injection in prefilled syringe
leo pharma a/s (0000003363) 55 industriparken, ballerup, 2750 - tinzaparin sodium - solution for injection in prefilled syringe - 10.000 anti-xa iu/0.5ml - tinzaparin sodium (8000001401) 10iu
antibiophilus 75mg/cap caps
remek ΦΑΡΜΑΚΑ-ΚΑΛΛΥΝΤΙΚΑ Α.Ε. - lactobacillus acidophilus, lyophilized - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 75mg/cap - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
nyxthracis (previously obiltoxaximab sfl)
sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - Άνοσοι οροί και ανοσοσφαιρίνες, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.